An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
- 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Apr 2016.